Rizatriptan Benzoate

CAS 145202-66-0 19 current records 1 historicalSmall Molecule

Who holds supplier records for Rizatriptan Benzoate? 19 organisations hold a current record for Rizatriptan Benzoate: an active US FDA Type II Drug Master File or a CEP. A further 1 organisation has only historical (inactive) DMF filings. 11 of them hold a valid EU Certificate of Suitability. Recorded organisation countries for current records: India (16), Spain (1), Taiwan (1) and China (1).

Sources: FDA Drug Master File list, EDQM certification database, FDA Orange Book. Record updated 16 Nov 2026. How we read these records

Cite as: PharmaTek, “Rizatriptan Benzoate: DMF and CEP holder records”, record as of 16 Nov 2026, pharmatek.co.uk/directory/api/rizatriptan-benzoate

Reading the evidence

  • 19 current records

    Several organisations hold current DMFs or CEPs. Whether any is a usable source for your grade, scale and market still needs qualification.

  • Most recorded organisations are in India

    16 of the 19 current records with a recorded country list India. Organisation country is not necessarily the manufacturing site.

  • 13 with a company-level GMP certificate on record

    These organisations have at least one current EU or UK GMP certificate somewhere. It is not matched to the site that makes this substance; check the certificate's site and scope.

  • US product patents listed

    The latest patent listed in the FDA Orange Book for an approved product containing Rizatriptan Benzoate expires 30 Jul 2034. Product, formulation and method-of-use patents do not by themselves stop the ingredient being supplied or other products being approved.

Current records (19)

Organisations holding an active US FDA Type II Drug Master File or a CEP for Rizatriptan Benzoate. Country is the organisation's recorded country, not necessarily the manufacturing site.

Need Rizatriptan Benzoate sourced and checked?

The Sourcing Desk contacts candidates, confirms current supply, grade and site, and screens each against its regulatory record, for a buyer-paid fixed fee and never a supplier commission.

Request sourcing help

Valid CEP holder entries (11)

Certificates of Suitability on the EDQM register for Rizatriptan Benzoate, including the salts, esters and hydrates the register lists separately; each row shows the substance as named on the certificate. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer. 15 certificates in total, including withdrawn, expired, suspended and repeat certificates.

HolderCountryCertificateIssuedEU GMP at holder's address
APOTEX PHARMACHEM INDIA PRIVATE LIMITED BangaloreIN
CEP 2013-206 - Rev 02
Rizatriptan benzoate
Sept 2026—
EMCURE PHARMACEUTICALS LIMITED PuneIN
CEP 2019-095 - Rev 03
Rizatriptan benzoate
Jun 2026—
MATRIX PHARMACORP PRIVATE LIMITED SangareddyIN
CEP 2011-299 - Rev 05
Rizatriptan benzoate
May 2026—
ALIVUS LIFE SCIENCES LIMITED MumbaiIN
CEP 2012-108 - Rev 04
Rizatriptan benzoate
May 2026—
JUBILANT BIOSYS LIMITED MysuruIN
CEP 2012-273 - Rev 03
Rizatriptan benzoate
Mar 2026—
APITORIA PHARMA PRIVATE LIMITED HyderabadIN
CEP 2011-201 - Rev 04
Rizatriptan benzoate
Jul 2025—
MACLEODS PHARMACEUTICALS LIMITED MumbaiIN
CEP 2025-054 - Rev 00
Rizatriptan benzoate, 1295
Jun 2025—
UNICHEM LABORATORIES LIMITED MumbaiIN
CEP 2014-290 - Rev 01
Rizatriptan benzoate
Nov 2024—
SMS PHARMACEUTICALS LIMITED HyderabadIN
R1-CEP 2013-028 - Rev 00
Rizatriptan benzoate
May 2020—
NATCO PHARMA LIMITED HyderabadIN
R1-CEP 2012-268 - Rev 00
Rizatriptan benzoate
May 2020—
DR. REDDY'S LABORATORIES LIMITED HyderabadIN
R1-CEP 2012-225 - Rev 00
Rizatriptan benzoate
May 2020—

The GMP column shows the most recent EU GMP certificate issued for the same address as the holder, joined on the EMA location identifier printed on both documents (EudraGMDP, re-read about once a quarter; withdrawn certificates are excluded). A dash means no certificate carries that identifier, not that the site is uninspected. The holder's address is not necessarily where the substance is made.

Certification Online Database. European Directorate for the Quality of Medicines & HealthCare (EDQM), Council of Europe, (2026), URL: https://extranet.edqm.eu/publications/recherches_CEP.shtml. Accessed 16 Nov 2026. Reproduced with permission and unaltered. The EDQM and the Council of Europe accept no liability for any consequence arising from its use.

Historical records (1)

Organisations whose Type II DMFs for Rizatriptan Benzoate are no longer active. These show a past filing, not current supply.

Show all 1 historical record
  • ALP PHARM BEIJING CO LTD
    Inactive DMF 25229 · filed Mar 2011

US product patents and exclusivity

The FDA Orange Book lists patents and exclusivities for specific approved products (22 listed products contain Rizatriptan Benzoate). The latest listed patent expires 30 Jul 2034. These dates are product-specific: they can cover a formulation, a combination or a method of use, and do not on their own show whether the ingredient is protected or whether generics are already approved. Check the individual product entries before planning a launch.

Other forms of this substance

A DMF or CEP is listed under the form it names. Salts, esters and hydrates of the same active substance have their own records:

Overview

Rizatriptan Benzoate is a selective serotonin 5-HT1B/1D receptor agonist used to treat migraine headaches. It works by narrowing blood vessels in the brain and reducing substances in the body that trigger headache pain, sensitivity to light and sound, and other migraine symptoms.

Chemical identity

IUPAC name
benzoic acid;N,N-dimethyl-2-[5-(1,2,4-triazol-1-ylmethyl)-1H-indol-3-yl]ethanamine
Canonical SMILES
CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3.C1=CC=C(C=C1)C(=O)O
InChIKey
JPRXYLQNJJVCMZ-UHFFFAOYSA-N
Synonyms
Maxalt API, maxalt, mk-0462, nsc-758919, rizafilm, symbravo component rizatriptan benzoate

Pharmacologic class

As the US FDA states it for this active substance on product listings.

Established pharmacologic class
Serotonin-1b and Serotonin-1d Receptor Agonist
Mechanism of action
Serotonin 1b Receptor Agonists; Serotonin 1d Receptor Agonists

Therapeutic areas

NeurologyPain Management

Record history

No change to the current records between 13 Nov 2026 and 16 Nov 2026.

Get an email when these records change: at most one a week, only when something changed, and only after you confirm your address. All changes this week

What these records establish

  • An active DMF means a confidential file is held by the FDA and can be referenced; the FDA does not approve or disapprove DMFs.
  • A CEP confirms monograph suitability for the EU market; it is not a GMP certificate, and the holder may not be the manufacturer.
  • Historical records show a past filing, not current supply.
  • Company GMP certificates are matched to the organisation, not to the site making this substance.
  • A substance missing from these registers is not evidence that no supplier exists.

Frequently asked questions

Which organisations hold current supplier records for Rizatriptan Benzoate?

19 organisations hold an active US FDA Type II Drug Master File or a CEP for Rizatriptan Benzoate: Natco Pharma (India), ALIVUS LIFE SCIENCES LTD (India), APITORIA PHARMA PRIVATE LTD (India), Dr. Reddy's Laboratories Ltd. (India), Emcure Pharmaceuticals Limited (India), JUBILANT BIOSYS LTD (India), Macleods Pharmaceuticals Ltd. (India) and MATRIX PHARMACORP PRIVATE LTD (India), and 11 more listed on this page. A DMF or CEP shows a regulatory filing, not current commercial availability, and the holder is not necessarily the manufacturing site.

Which Rizatriptan Benzoate Drug Master Files are active?

Natco Pharma (DMF 20781, 22763), ALIVUS LIFE SCIENCES LTD (DMF 22676), APITORIA PHARMA PRIVATE LTD (DMF 23814), Dr. Reddy's Laboratories Ltd. (DMF 19179), Emcure Pharmaceuticals Limited (DMF 25764), JUBILANT BIOSYS LTD (DMF 24054), Macleods Pharmaceuticals Ltd. (DMF 24552) and MATRIX PHARMACORP PRIVATE LTD (DMF 19098) and 10 more. The FDA does not approve or disapprove DMFs; an active DMF can be referenced in an application once its holder issues a letter of authorisation.

What do the historical Rizatriptan Benzoate records mean?

1 organisation has only inactive Type II DMFs for Rizatriptan Benzoate. An inactive DMF records that a filing once existed; it does not show that the organisation supplies the substance today.

Does Rizatriptan Benzoate have a European Certificate of Suitability?

Yes. 11 organisations hold a valid CEP for Rizatriptan Benzoate on the EDQM register, including APOTEX PHARMACHEM INDIA PRIVATE LIMITED Bangalore (IN), EMCURE PHARMACEUTICALS LIMITED Pune (IN), MATRIX PHARMACORP PRIVATE LIMITED Sangareddy (IN), ALIVUS LIFE SCIENCES LIMITED Mumbai (IN), JUBILANT BIOSYS LIMITED Mysuru (IN) and APITORIA PHARMA PRIVATE LIMITED Hyderabad (IN) and 5 more. A CEP confirms the substance can be controlled by the European Pharmacopoeia monograph; it is not a GMP certificate, and the holder is not necessarily the manufacturer.

Does the FDA Orange Book list patents for products containing Rizatriptan Benzoate?

Yes. The latest patent listed for an approved US product containing Rizatriptan Benzoate expires 30 Jul 2034, across 22 listed products. These patents protect specific products, formulations or uses. They do not by themselves mean the ingredient is protected, and generic versions of other products may already be approved.

How do I qualify a Rizatriptan Benzoate supplier?

Confirm the DMF or CEP is current and covers your grade, obtain the letter of authorisation, identify the actual manufacturing site and check its GMP certificate and FDA inspection history, audit the site or review a recent audit, and run comparable requests for information across more than one candidate.

For suppliers

Do you supply Rizatriptan Benzoate?

Send a link to a certificate, registration or filing we have missed or got wrong. We check it against the issuing register before changing anything; information we cannot check against a register is shown as supplier-reported.

Free. Payment never buys an evidence status.